Last reviewed · How we verify
NCT05698316: INTERCEPT-AMD
A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression
trial testing Collection of both retrospective and prospective data collection in 3 visits. in Age Related Macular Degeneration in 1,000 participants. Participants enrolled and being followed up; not accepting new ones.
22 February 2024
Quick facts
| Lead sponsor | Association for Innovation and Biomedical Research on Light and Image |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 4 May 2023 |
| Primary completion | 22 February 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 25 locations across France, Italy, Netherlands, Ireland, United Kingdom, Germany, Switzerland, Portugal |
Drugs / interventions tested
- Collection of both retrospective and prospective data collection in 3 visits.
Conditions studied
- Age Related Macular Degeneration — all drugs for Age Related Macular Degeneration →
- Intermediate AMD — all drugs for Intermediate AMD →
- Atrophy — all drugs for Atrophy →
- Prediction — all drugs for Prediction →
Sponsor
Association for Innovation and Biomedical Research on Light and Image
Who can join
Eligibility, any sex, with Age Related Macular Degeneration or Intermediate AMD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicentre retrospective and prospective cohort study with the goal to develop a well-characterised multimodal image database of eyes with intermediate AMD with and without early atrophy. The main objectives are: 1. Develop a collaborative well-characterised database on intermediate AMD with or without early atrophy. 2. Grading of these images to explore imaging markers of progression. 3. Develop predictive models as a secondary analysis of our dataset. This study will recruit around 1.000 eyes in 6 months. All consenting patients who have had at least 3 clinic visits with multimodal imaging done at least at 6 months interval between 2 visits and meet the inclusion and exclusion criteria will be included in the study for retrospective data collection. Those with one visit remaining to complete 2 years, images will be acquired prospectively. In addition to the images, routine demographic data (age and sex) and available visual acuity (VA) (BCVA if possible, VA with Pinhole or VA with patient's glasses) will be collected. Multimodal imaging includes mandated macular OCT with or without enhanced depth imaging and infrared imaging. Fundus autofluorescence (AF) and multicolor imaging are optional. All imaging must be done on Heidelberg Spectralis system.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Human retinal secretome: A cross-link between mesenchymal and retinal cells.
Donato L, Scimone C, Alibrandi S, Scalinci SZ, et al · · 2023 · cited 6× · PMID 37545752 · DOI 10.4252/wjsc.v15.i7.665
Verify or expand the search:
- PubMed search for NCT05698316
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age Related Macular Degeneration
Currently open trials in the same condition.
- NCT07461441 — Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal · Phase 3 · recruiting
- NCT07235527 — Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degener · recruiting
- NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
- NCT03102138 — Retinal Pigment Epithelium Safety Study for Patients in B4711001 · active not recruiting
- NCT04697095 — Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants · NA · recruiting
Other Association for Innovation and Biomedical Research on Light and Image trials
Trials by the same sponsor.
- NCT06066021 — Evaluation of a Health Education Program for Type 2 Diabetes Patients · NA · completed
- NCT05735730 — Can the Risk for AMD be Modulated? · NA · active not recruiting
- NCT05746975 — Diabetic Retinopathy Classification: ETDRS 7-fields vs Widefield Imaging (ClarusDR) · completed
- NCT05581225 — Prediction of Progression of Retinal Ischemia in Diabetes · active not recruiting
- NCT04636307 — Characterization of Retinal Disease Progression in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 U · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05698316 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Association for Innovation and Biomedical Research on Light and Image
- Last refreshed: 30 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05698316.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing